Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lantheus (LNTH)
NASDAQ:LNTH
Holding LNTH?
Track your performance easily
LNTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$50.20 - $126.89
Previous CloseN/A
Volume177.90K
Average Volume (3M)802.13K
Market Cap
$6.44B
Enterprise Value$7.77B
Total Cash (Recent Filing)$51.18M
Total Debt (Recent Filing)$274.46M
Price to Earnings (P/E)15.5
Beta0.38
Next Earnings
Feb 20, 2025EPS Estimate
1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.02
Shares Outstanding69,526,840
10 Day Avg. Volume762,622
30 Day Avg. Volume802,135
Standard Deviation0.17
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.52
Price to Cash Flow (P/CF)19.20
P/FCF Ratio41.00
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue5.19
Enterprise Value/Gross Profit10.96
Enterprise Value/Ebitda17.67
Forecast
1Y Price Target
$131.29Price Target Upside43.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Lantheus News
PremiumCompany Announcements
Lantheus Acquires Life Molecular Imaging for $350 Million
PremiumCompany Announcements
Lantheus Announces Departure of Chief Medical Officer
Bulls Say, Bears Say
Bulls Say
Financial Performance3Q revenues were ahead of expectations, with PYLARIFY and Precision Diagnostics both showing significant growth.
Market OpportunityThe deal positions Lantheus to capture share in what management estimates could be a $2.5B US Alzheimer's Disease PET radiodiagnostic market opportunity by the mid-2030s.
Strategic AcquisitionLantheus' acquisition of Life Molecular Imaging for $350M upfront represents a strategically compelling move to further entrench itself in the growing Alzheimer's Disease radiodiagnostic market.
Bears Say
Financial PerformanceThe updated annual guidance implied a softer-than-anticipated 4Q in both sales and EPS.
Product Growth ConcernsWeakness in LNTH's share price has been driven by concern over PYLARIFY's growth trajectory and disappointment over the updated SPLASH results.
Regulatory And Market UncertaintyThe uncertainty remains whether CMS will update the OPPS rule in FY25, creating ambiguity for LNTH stock.
---
Ownership Overview
2.11% Insiders
37.42% Mutual Funds
2.45% Other Institutional Investors
31.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $50.20 and its highest was $126.89 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $6.44B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Feb 20, 2025 which is in 33 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Nov 06, 2024. The company reported $1.7 earnings per share for the quarter, beating the consensus estimate of $1.556 by $0.144.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.55.
How many shares outstanding does Lantheus have?
Lantheus has 69,526,840 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.7 in its last earnings report, beating expectations of $1.556. Following the earnings report the stock price went down -20.694%.
Which hedge fund is a major shareholder of Lantheus?
Among the largest hedge funds holding Lantheus’s share is Farallon Capital Management, L.L.C.. It holds Lantheus’s shares valued at 324M.
---
Lantheus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$131.29 (43.36% Upside)
$131.29 (43.36% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 830.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
65.60%
12-Months-Change
Fundamentals
Return on Equity
45.53%
Trailing 12-Months
Asset Growth
34.70%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
---
LNTH Company Deck
---
LNTH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong growth in flagship products like PYLARIFY and DEFINITY, boosted by strategic initiatives and positive regulatory developments. However, these were slightly tempered by sequential revenue declines and challenges with clinical trials for PNT2002. Overall, the financial performance and strategic advancements support a positive outlook.Read More>---
LNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
---
LNTH Stock 12 Month Forecast
Average Price Target
$131.29
▲(43.36% Upside)
Technical Analysis
Exact Sciences
―
Guardant Health
―
Natera
―
QuidelOrtho
―
Fulgent Genetics
―
Telesis Bio
―
Best Analysts Covering LNTH
1 Year
1 Year Success Rate
20/28 ratings generated profit
1 Year Average Return
+54.40%
assigned a buy rating 5 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +54.40% per trade.
---